Table 1.
Baseline demographic and clinical characteristics of patients included in the analysis
| Patient | Sex | Age (years) | Year of diagnosis | Date of eculizumab initiation | MGFA class before eculizumab initiation | Thymectomya | Medication in previous 12 months |
| 1 | F | 57 | 2015 | June 2018 | IIa | Y (2 years ago) | Prednisone (50 mg/day), pyridostigmine (60 mg TID), IVIG (1 g/kg q4w), mycophenolate (1000 mg BID) |
| 2 | F | 50 | 2016 | August 2018 | IIIa | Y (5 years ago) | Prednisone (40 mg/day), pyridostigmine (60 mg TID), IVIG (1 g/kg q4w), azathioprine (100 mg BID) |
| 3 | F | 45 | 2015 | November 2018 | IIb | Y (6 years ago) | IVIG (1 g/kg q4w), pyridostigmine (60 mg QID), prednisone (30 mg/day) |
| 4 | F | 59 | 2015 | September 2018 | IIa | N | Prednisone (50 mg/day), mycophenolate (1000 mg BID), pyridostigmine (60 mg TID) |
| 5 | F | 34 | 2016 | September 2018 | IIIa | N | PLEX (5 courses q4w), pyridostigmine (60 mg TID), prednisone (50 mg/day) |
| 6 | F | 60 | 2015 | July 2018 | IIIb | Y (4 years ago) | PLEX (5 courses q4w), prednisone (40 mg/day), pyridostigmine (60 mg TID) |
aPatient 1 had no abnormal histopathologic findings; Patients 2, 3, and 6 had thymus hyperplasia. BID, twice daily; F, female; IVIG, intravenous immunoglobulin; MGFA, Myasthenia Gravis Foundation of America; N, no; PLEX, plasma exchange; q4w, every 4 weeks; QID, four times daily; TID, three times daily; Y, yes.